Open Access

EPA based therapy in CAD: What do we know?

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
Sponsored by PACE-CME

Congress Session

About the speaker

Professor Lale Tokgozoglu

Hacettepe University, Ankara (Turkey)
27 presentations
0 follower

2 more presentations in this session

Unravelling the triglycerides story: Lessons from genetics and clinical trials.

Speaker: Professor P. Libby (Boston, US)

Thumbnail

Integrating EPA based therapy in the management of residual risk.

Speaker: Professor P. Steg (Paris, FR)

Thumbnail

Access the full session

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Speakers: Professor L. Tokgozoglu, Professor P. Libby, Professor P. Steg
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

An asymptomatic patient with positive treadmill test during screening for life insurance and significant proximal LAD disease in coronary CT angiography: how to implement the guidelines and take-home message.

27 August 2021

ESC Premium Access

An asymptomatic patient with positive treadmill test during screening for life insurance and significant proximal LAD disease in coronary CT angiography: what do the guidelines say?

27 August 2021

ESC Premium Access

Endothelial barrier function and post-COVID consequences

27 August 2021

This platform is supported by

logo Novo Nordisk